Last edition
News about "Antibody Drug Conjugate (ADC) "
Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer
Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.
Antibody Drug Conjugate (ADC) | 22/05/2026 | By News Bureau
US FDA Approves Enhertu for New Early Breast Cancer Indications
Enhertu receives new US approvals for use before and after surgery in HER2-positive breast cancer, supported by positive DESTINY-Breast11 and DESTINY-Breast05 phase 3 trial results.
Antibody Drug Conjugate (ADC) | 18/05/2026 | By News Bureau
Mabwell Launches Phase 3 Trial of Nectin-4 ADC 9MW2821 for Triple-Negative Breast Cancer
Mabwell launches Phase 3 study of 9MW2821, the world’s first Nectin-4 ADC for TNBC, marking its fourth pivotal clinical trial.
Antibody Drug Conjugate (ADC) | 23/04/2026 | By News Bureau | 120
GSK Reports Positive Data for B7-H4 ADC in Gynecological Cancers
GSK reports positive BEHOLD-1 data for B7-H4 ADC mocertatug rezetecan, showing strong response rates in ovarian and endometrial cancers, with Phase 3 trials planned.
Antibody Drug Conjugate (ADC) | 14/04/2026 | By News Bureau | 112
Orum Therapeutics Appoints Dr Chad May as Chief Scientific Officer
Orum Therapeutics has appointed Dr Chad May, PhD, as Chief Scientific Officer (CSO), who brings over two decades of oncology and immunology research experience to advance the company’s degrader-antibody conjugate platform and pipeline of next-generation therapies.
Antibody Drug Conjugate (ADC) | 05/01/2026 | By News Bureau | 167
Daiichi Sankyo has dosed the first patient in a phase 1 clinical trial of DS3610, its investigational STING agonist Antibody Drug Conjugate (ADC), marking a key step in advancing novel immunotherapy approaches for patients with advanced solid tumours.
Antibody Drug Conjugate (ADC) | 12/11/2025 | By Dineshwori | 727
Daiichi Sankyo Files sNDA in Japan for ENHERTU Plus Pertuzumab in HER2-Positive Breast Cancer
Daiichi Sankyo has filed a supplemental NDA in Japan for ENHERTU plus Pertuzumab in HER2-positive breast cancer. If approved, this therapy could enter the first-line metastatic setting and has the potential to become a new standard of care.
<br />
Antibody Drug Conjugate (ADC) | 08/10/2025 | By Dineshwori | 534
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy